Zydus Lifesciences Ltd. on Thursday said it has received final approval from the US health regulator to market its generic version of Dapsone gel used to treat acne.
The final approval by the US Food and Drug Administration is for Dapsone gel of strength 7.5%, Zydus Lifesciences said in a regulatory filing.
Dapsone gel is used to treat acne and will be manufactured at the group's topical manufacturing facility in Changodar, Ahmedabad, it added.
ADVERTISEMENT
Dapsone gel, 7.5% had annual sales of $35.8 million in the US, Zydus Lifesciences said citing IQVIA MAT March 2024 data.
ADVERTISEMENT
RECOMMENDED FOR YOU
Biocon Biologics Granted Marketing Authorisation By European Commission For Bone Disease Medicines
Jul 03, 2025
India Pushes For Social Security Pacts In FTAs, Awaits US Nod
Jul 02, 2025
JK Cement Dividend: Shareholders At AGM To Consider Issuing Nod — Check Record Date, Other Details
Jun 30, 2025
Wegovy Vs Mounjaro Vs Ozempic: Obesity And Diabetes Treatment Drugs Compared
Jun 25, 2025
POPULAR
1
Stock Market Live: Nifty, Sensex Extend Losses As RIL, ICICI Bank Shares Weigh
2
Value Vs Momentum Investing: THIS Market Veteran Prefers One Over The Other — Here's Why
3
Tech Layoffs 2025: Intel Cuts Over 500 Jobs; Joins Google, Microsoft In Latest Wave Of Mass Firings
4
Lodha Developers Can Rally 36% Says Motilal Oswal Maintaining 'Buy'
5